Replimune Group initiated at BMO Capital

Replimune Group initiated with an Outperform at BMO Capital. As reported earlier, BMO Capital analyst Do Kim initiated Replimune with an Outperform rating and a price target of $31, saying its platform has been “significantly de-risked” based on its “structural similarity to T-Vec, the only FDA-approved oncolytic virus.” The analyst contends that Replimune’s RP1 is better than T-Vec, with a ” more potent HSV-1 strain and addition of fusogenic protein GALV”, and can deliver on rising expectations for oncolytic viruses helped by the advent of immunotherapy.

https://bit.ly/2BgNDLI